December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
Cancer
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in...
Mayo Clinic Jacksonville Comes Online as Third Site in Breathe BioMedical’s Ongoing Multi-Center Clinical Study to Develop a Breath Test for Early Detection of Breast Cancer in Females with Dense Breasts
Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - December 16, 2025) - Breathe BioMedical, a company developing a breath analytics...
Detect-ION Launches Collaborative Project to Develop Breath-Based Diagnostics for Pneumonia-Causing Pathogens
TAMPA, Fla., Dec. 15, 2025 /PRNewswire/ -- Detect-ION, LLC, a health-tech startup based in Tampa, FL, today announced a collaborative...
Helio Genomics Forms Strategic Partnership with LiverRight Aimed at Broadening Nationwide Access to Early Liver Cancer Detection
Combining breakthrough blood-based test with same-week access to board-certified hepatologists in all 50 statesIRVINE, Calif., Dec. 15, 2025 /PRNewswire/ --...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology...
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial...
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest...
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food...
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...